blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3148532

EP3148532 - PHARMACEUTICAL COMBINATION COMPRISING A CDK INHIBITOR AND A THIOREDOXIN REDUCTASE INHIBITOR FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
Former [2017/14]PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER
[2020/49]
StatusNo opposition filed within time limit
Status updated on  07.01.2022
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  29.01.2021
FormerGrant of patent is intended
Status updated on  15.12.2020
FormerExamination is in progress
Status updated on  22.11.2019
FormerRequest for examination was made
Status updated on  03.03.2017
FormerThe international publication has been made
Status updated on  21.12.2016
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Piramal Enterprises Limited
Piramal Tower
Ganpatrao Kadam Marg
Lower Parel
Mumbai 400 013 / IN
[2017/14]
Inventor(s)01 / ORWAR, Owe
Askims Kyakva 6
S-43651 Hovas / SE
02 / SRINIVASA, Sreesha
N104
Renaissance Exotica
Jakkur Plantation
Jakkuru, Bangalore
Bangalore Karnataka 560064 / IN
03 / MISHRA, Prabha
B-7/56
Century Rayon colony
Shahad
Kalyan Thane 421103 / IN
 [2017/14]
Representative(s)Avidity IP
Broers Building
Hauser Forum
21 JJ Thomson Avenue
Cambridge CB3 0FA / GB
[2021/09]
Former [2017/14]Cummings, Ross Martin, et al
Avidity IP
Broers Building
Hauser Forum
21 J.J. Thomson Avenue
Cambridge CB3 0FA / GB
Application number, filing date15799889.927.05.2015
[2017/14]
WO2015IB53963
Priority number, dateUS201462003575P28.05.2014         Original published format: US 201462003575 P
[2017/14]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015181737
Date:03.12.2015
Language:EN
[2015/48]
Type: A1 Application with search report 
No.:EP3148532
Date:05.04.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 03.12.2015 takes the place of the publication of the European patent application.
[2017/14]
Type: B1 Patent specification 
No.:EP3148532
Date:03.03.2021
Language:EN
[2021/09]
Search report(s)International search report - published on:AU03.12.2015
(Supplementary) European search report - dispatched on:EP06.12.2017
ClassificationIPC:A61K31/4025, A61K31/4412, A61K31/425, A61K31/513, A61K31/28, A61P35/00, A61K45/06, A61K31/41, A61K31/519, A61K31/553, A61K31/7135, A61K33/36
[2018/01]
CPC:
A61K31/4025 (EP,US); A61K31/41 (EP,US); A61K31/513 (EP,US);
A61K31/519 (EP,US); A61K31/553 (EP,US); A61K31/7135 (EP,US);
A61K33/36 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP) (-)
C-Set:
A61K31/4025, A61K2300/00 (US,EP);
A61K31/41, A61K2300/00 (EP,US);
A61K31/513, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (EP,US);
A61K31/553, A61K2300/00 (US,EP);
A61K31/7135, A61K2300/00 (EP,US)
(-)
Former IPC [2017/14]A61K31/4025, A61K31/4412, A61K31/425, A61K31/513, A61K31/28, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/14]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:PHARMAZEUTISCHE KOMBINATION, DIE EINEN CDK-INHIBITOR UND EINEN THIOREDOXIN-REDUKTASE-INHIBITOR ENTHÄLT, ZUR BEHANDLUNG VON KREBS[2020/49]
English:PHARMACEUTICAL COMBINATION COMPRISING A CDK INHIBITOR AND A THIOREDOXIN REDUCTASE INHIBITOR FOR THE TREATMENT OF CANCER[2020/49]
French:ASSOCIATION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE CDK ET UN INHIBITEUR DE THIORÉDOXINE RÉDUCTASE POUR LE TRAITEMENT DU CANCER[2020/49]
Former [2017/14]PHARMAZEUTISCHE KOMBINATIONEN ZUR BEHANDLUNG VON KREBS
Former [2017/14]PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER
Former [2017/14]ASSOCIATION PHARMACEUTIQUE POUR LE TRAITEMENT DU CANCER
Entry into regional phase20.12.2016National basic fee paid 
20.12.2016Search fee paid 
20.12.2016Designation fee(s) paid 
20.12.2016Examination fee paid 
Examination procedure20.12.2016Examination requested  [2017/14]
20.12.2016Date on which the examining division has become responsible
29.06.2018Amendment by applicant (claims and/or description)
27.11.2019Despatch of a communication from the examining division (Time limit: M06)
05.06.2020Reply to a communication from the examining division
16.12.2020Communication of intention to grant the patent
22.01.2021Fee for grant paid
22.01.2021Fee for publishing/printing paid
22.01.2021Receipt of the translation of the claim(s)
Opposition(s)06.12.2021No opposition filed within time limit [2022/06]
Fees paidRenewal fee
30.05.2017Renewal fee patent year 03
29.05.2018Renewal fee patent year 04
28.05.2019Renewal fee patent year 05
27.05.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.05.2015
AL03.03.2021
AT03.03.2021
CY03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
MC03.03.2021
MK03.03.2021
MT03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SI03.03.2021
SK03.03.2021
SM03.03.2021
LU27.05.2021
CH31.05.2021
LI31.05.2021
BG03.06.2021
GR04.06.2021
IS03.07.2021
PT05.07.2021
[2024/41]
Former [2024/22]HU27.05.2015
AL03.03.2021
AT03.03.2021
CY03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
MC03.03.2021
MK03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SI03.03.2021
SK03.03.2021
SM03.03.2021
LU27.05.2021
CH31.05.2021
LI31.05.2021
BG03.06.2021
GR04.06.2021
IS03.07.2021
PT05.07.2021
Former [2023/30]HU27.05.2015
AL03.03.2021
AT03.03.2021
CY03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
MC03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SI03.03.2021
SK03.03.2021
SM03.03.2021
LU27.05.2021
CH31.05.2021
LI31.05.2021
BG03.06.2021
GR04.06.2021
IS03.07.2021
PT05.07.2021
Former [2023/27]HU27.05.2015
AL03.03.2021
AT03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
MC03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SI03.03.2021
SK03.03.2021
SM03.03.2021
LU27.05.2021
CH31.05.2021
LI31.05.2021
BG03.06.2021
GR04.06.2021
IS03.07.2021
PT05.07.2021
Former [2022/23]AL03.03.2021
AT03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
MC03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SI03.03.2021
SK03.03.2021
SM03.03.2021
LU27.05.2021
CH31.05.2021
LI31.05.2021
BG03.06.2021
GR04.06.2021
IS03.07.2021
PT05.07.2021
Former [2022/11]AL03.03.2021
AT03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
MC03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SI03.03.2021
SK03.03.2021
SM03.03.2021
LU27.05.2021
CH31.05.2021
LI31.05.2021
BG03.06.2021
GR04.06.2021
PT05.07.2021
Former [2022/10]AL03.03.2021
AT03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
MC03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SK03.03.2021
SM03.03.2021
LU27.05.2021
CH31.05.2021
LI31.05.2021
BG03.06.2021
GR04.06.2021
PT05.07.2021
Former [2022/09]AL03.03.2021
AT03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
MC03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SK03.03.2021
SM03.03.2021
LU27.05.2021
BG03.06.2021
GR04.06.2021
IS03.07.2021
PT05.07.2021
Former [2022/07]AL03.03.2021
AT03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
MC03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SK03.03.2021
SM03.03.2021
BG03.06.2021
GR04.06.2021
IS03.07.2021
PT05.07.2021
Former [2021/51]AT03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SK03.03.2021
SM03.03.2021
BG03.06.2021
GR04.06.2021
IS03.07.2021
PT05.07.2021
Former [2021/50]AT03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
PL03.03.2021
RO03.03.2021
RS03.03.2021
SK03.03.2021
SM03.03.2021
BG03.06.2021
GR04.06.2021
PT05.07.2021
Former [2021/48]AT03.03.2021
CZ03.03.2021
EE03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
PL03.03.2021
RS03.03.2021
SM03.03.2021
BG03.06.2021
GR04.06.2021
Former [2021/46]AT03.03.2021
FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
PL03.03.2021
RS03.03.2021
SM03.03.2021
BG03.06.2021
GR04.06.2021
Former [2021/39]FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
PL03.03.2021
RS03.03.2021
BG03.06.2021
GR04.06.2021
Former [2021/37]FI03.03.2021
HR03.03.2021
LT03.03.2021
LV03.03.2021
RS03.03.2021
BG03.06.2021
GR04.06.2021
Former [2021/36]FI03.03.2021
HR03.03.2021
LT03.03.2021
BG03.06.2021
GR04.06.2021
Former [2021/35]FI03.03.2021
HR03.03.2021
LT03.03.2021
Former [2021/33]FI03.03.2021
LT03.03.2021
Documents cited:Search[XI]  - D. RATHKOPF ET AL, "Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors", CLINICAL CANCER RESEARCH, US, (20091124), vol. 15, no. 23, doi:10.1158/1078-0432.CCR-09-1502, ISSN 1078-0432, pages 7405 - 7411, XP055428648 [X] 1,2,4,7-9,11,14 * abstract * * figure 1; table 4 * [I] 3,5,6,10,12,13

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-09-1502
 [XI]  - Michael J Pishvaian, "Abstract 5047: Synergistic anti-cancer activity of the CDK4/6 inhibitor PD-0332991 in combination with 5-fluorouracil-based chemotherapy in human colon cancer cells | Cancer Research", Cancer Research, doi:10.1158/1538-7445.AM10-5047, (20100415), URL: http://cancerres.aacrjournals.org/content/70/8_Supplement/5047, (20161024), XP055313469 [X] 1,2,4,7-9,11,14 * abstract * [I] 3,5,6,10,12,13

DOI:   http://dx.doi.org/10.1158/1538-7445.AM10-5047
 [XI]  - BIBLE K C ET AL, "CYTOXIC SYNERGY BETWEEN FLAVOPIRIDOL (NSC 649890, l86-8275) AND VARIOUS ANTINEOPLASTIC AGENTS: THE IMPORTANCE OF SEQUENCE OF ADMINISTRATION", CANCER RESEARCH, AACR - AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (19970815), vol. 57, ISSN 0008-5472, pages 3375 - 3380, XP002128085 [X] 1,2,4,7-9,11,14 * abstract * * figure 2 * * page 3380, column 1, paragraph second but last * [I] 3,5,6,10,12,13
 [A]  - MALINI GUHA, "Cyclin-dependent kinase inhibitors move into PhaseIII", NATURE REVIEWS. DRUG DISCOVERY, GB, (201212), vol. 11, no. 12, doi:10.1038/nrd3908, ISSN 1474-1776, pages 892 - 894, XP055428903 [A] 1-14 * page 894 *

DOI:   http://dx.doi.org/10.1038/nrd3908
 [A]  - JONAS CICENAS ET AL, "The CDK inhibitors in cancer research and therapy", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER, BERLIN, DE, (20110830), vol. 137, no. 10, doi:10.1007/S00432-011-1039-4, ISSN 1432-1335, pages 1409 - 1418, XP019951971 [A] 1-14 * paragraph [0001] *

DOI:   http://dx.doi.org/10.1007/s00432-011-1039-4
International search[A]WO2008057402  (CYTOVIA INC [US], et al) [A] 1-14 * Abstract; paragraphs 1, 93; claims 17, 38 *;
 [A]WO2009076170  (NOVARTIS AG [CH], et al) [A] 1-14 * Abstract; page 5, xxxi; page 16, first complete paragraph; claims 1, 6 *;
 [A]WO2009137378  (SCHERING CORP [US], et al) [A] 1-14 * Abstract; page 4, line 20; page 5, line 9; page 8, line 10; page 24,line 29; page 26, line 6; claim 23 *;
 [A]WO2010129858  (UNIV GEORGIA STATE RES FOUND [US], et al) [A] 1-14 * Abstract; page 2, lines 21-23; page 3 line 24; page 85, lines 14-18; page 88, line 30, figure 6, claim 40 *;
 [A]WO2012125510  (GILEAD CALISTOGA LLC [US], et al) [A] 1-14 * Paragraphs 49, 195, 256, claim 19 *;
 [A]WO2012123889  (PIRAMAL HEALTHCARE LTD [IN], et al) [A] 1-14 * Abstract *;
 [A]WO2012164497  (PIRAMAL ENTPR LTD [IN], et al) [A] 1-14* Abstract (Formula I) *;
 [A]  - LIU, Z-M. et al., "Suppression of TG-Interacting Factor Sensitizes Arsenic Trioxide- Induced Apoptosis in Human Hepatocellular Carcinoma Cells", Biochemical Journal, (20110000), vol. 438, pages 349 - 358, XP055361152 [A] 1-14 * Abstract *

DOI:   http://dx.doi.org/10.1042/BJ20101653
by applicantUS5284856
 WO9720842
 WO03062236
 WO2004004632
 WO2004104007
 WO2005077954
 WO2007140222
 WO2007148158
 WO2010075074
 WO2012164497
    - BIBLEKAUFMANN, Cancer Res., (19970000), vol. 57, pages 3375 - 3380
    - D. RATHKOPF, Clin. Cancer Res, (20090000), vol. 15, pages 7405 - 7411
    - M.J.PISHAVIAN, Phase I study ofjlavopiridol with oxaliplatin andfluorouracillleucovorin in advance solid tumors
    - Free Radic. Biol. Med., (20010000), vol. 31, page 1287 1312
    - Cent. Nerv. Syst. Agents Med. Chem., (20100000), vol. 10, no. 4, pages 287 - 297
    - Free Radic. Biol. Med., (20100000), vol. 49, no. 11, pages 1603 - 1616
    - Cancer Res., (20100000), vol. 70, page 440
    - J. Biol. Chem., (20020000), vol. 277, pages 39456 - 62
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.